Upgrade to SI Premium - Free Trial

Form 3 Telix Pharmaceuticals For: Mar 18 Filed by: Patti Darren Joel

April 1, 2026 7:24 AM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Patti Darren Joel
(Last) (First) (Middle)
C/O TELIX PHARMACEUTICALS LTD
55 FLEMINGTON RD
(Street)
NORTH MELBOURNE 3051
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Group Chief Operating Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 25,558
D
American Depositary Receipts (1) 804
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Share Appreciation Rights (right to buy) (2) 04/04/2027 Ordinary Shares 15,826 4.95 (3) D
Share Rights (4) 01/11/2028 Ordinary Shares 15,000 0 D
Share Rights (5) 03/12/2027 Ordinary Shares 12,541 0 D
Performance Share Appreciation Rights (right to buy) (6) 12/21/2027 Ordinary Shares 27,448 6.9 (3) D
Share Rights (7) 01/11/2029 Ordinary Shares 15,000 0 D
Explanation of Responses:
1. Each American Depositary Receipt (ADR) is convertible at any time, at the holders election, into one ordinary share of the issuer. The ADRs have no expiration date.
2. The performance share appreciation rights (PSARs) were granted on April 5, 2022, and became vested and excercisable on March 6, 2025.
3. Conversion price is reported in Australian Dollars.
4. The share rights (SRs) were granted on November 1, 2023 and will become vested and exercisable on November 1, 2026, subject to continued service with the issuer. Each SR represents the contingent right to receive one ordinary share.
5. The SRs were granted on March 18, 2026 and will become auto-vested and exercised in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share (or ADR). See footnote (1).
6. The PSARs were granted on May 2, 2023, and became vested and exercisable on March 12, 2026.
7. The SRs were granted on November 1, 2023 and will become vested and exercisable on November 1, 2027, subject to continued service with the issuer. Each SR represents the contingent right to receive one ordinary share.
Remarks:
Ex. 24 - Power of Attorney
/s/ Oliver Newman, on behalf of Dr. Darren Patti, Group COO 04/01/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

EX-24

Categories

SEC Filings